Medical Information
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

HEMABATE®Principal Display Panel (carboprost tromethamine)

PRINCIPAL DISPLAY PANEL - 1 mL Ampoule Label

1 mL
NDC 0009-0856-05

Rx only

Hemabate®
carboprost tromethamine
injection, USP

250 mcg*

FOR INTRAMUSCULAR USE ONLY
Refrigerate at 2° to 8°C (36° to 46°F).
DOSAGE AND USE:
See accompanying
prescribing information.
*Equivalent to 250 mcg carboprost.
Distributed by Pharmacia & Upjohn Co
Division of Pfizer Inc, NY, NY 10017

PAA043229

LOT
EXP

Principal Display Panel - 1 mL Ampoule Label

PRINCIPAL DISPLAY PANEL - 10 Single-Dose Ampoule Carton

NDC 0009-0856-08
Contains 10 of NDC 0009-0856-05

Rx only

10–1 mL Single-Dose Ampoules

Hemabate®
carboprost tromethamine
injection, USP

250 mcg*

FOR INTRAMUSCULAR USE ONLY

Pfizer Injectables

Principal Display Panel - 10 Single-Dose Ampoule Carton
Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

*9AM-5PM ET Monday to Friday; excluding holidays.

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch